{
  "_metadata": {
    "version": "2.0",
    "ticker": "TEMPLATE",
    "asset_name": "asset"
  },
  "asset": {
    "name": "Lead Asset",
    "ticker": "TEMPLATE",
    "modality": "Small molecule",
    "stage": "Phase 2",
    "one_liner": "One sentence asset description",
    "ownership": "Wholly-owned"
  },
  "target": {
    "name": "TARGET",
    "full_name": "Full Target Name",
    "class": "Receptor / Kinase / etc",
    "pathway": "Pathway description",
    "biology": {
      "simple_explanation": "Plain English explanation of target biology - REQUIRED",
      "downstream_effects": ["Effect 1", "Effect 2"]
    },
    "why_good_target": {
      "clinical_validation": "Evidence from approved drugs or clinical data",
      "genetic_validation": {
        "gain_of_function": "GoF phenotype",
        "loss_of_function": "LoF protective effect"
      }
    }
  },
  "indications": {
    "lead": {
      "name": "Lead Indication",
      "stage": "Phase 2",
      "rationale": "Why this indication"
    },
    "expansion": [
      {
        "name": "Expansion Indication",
        "stage": "Planned",
        "rationale": "Why pursue"
      }
    ]
  },
  "clinical_data": {
    "trial_name": "TRIAL-1 (NCT00000000)",
    "trial_design": {
      "phase": "Phase 1/2",
      "design": "Open-label, multi-center study",
      "enrollment": "100 patients"
    },
    "populations": {
      "efficacy_population": {
        "n": 80,
        "description": "Evaluable patients"
      }
    },
    "efficacy_results": {
      "orr": "45%",
      "cr_rate": "10%",
      "dor_median": "18 months",
      "pfs_median": "12 months"
    },
    "safety": {
      "discontinuation_rate": "5%",
      "dose_reduction_rate": "15%",
      "common_ae_1": "20%",
      "common_ae_2": "15%"
    }
  },
  "catalysts": [
    {
      "event": "Phase 2 data readout",
      "timing": "Q2 2026",
      "importance": "critical",
      "what_to_watch": "ORR and safety profile"
    }
  ],
  "competitive_landscape": {
    "competitors": [
      {
        "drug": "Competitor Drug",
        "company": "Company Name",
        "limitation": "Why our asset is better"
      }
    ],
    "our_advantages": [
      "Advantage 1",
      "Advantage 2"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "35%",
    "peak_sales_estimate": "$1-2B",
    "key_risks": [
      "Risk 1",
      "Risk 2"
    ]
  },
  "market_opportunity": {
    "tam": "$5B",
    "patient_population": "50,000 patients annually",
    "unmet_need": "Description of unmet medical need"
  }
}
